Diffuse parenchymal lung diseases (DPLD) are a heterogeneous group of more than 100 different, rare entities which are distinct in view of underlying trigger events but share development of lung fibrosis as a consequence. As the triggering mechanisms are largely unexplained, treatment modalities are limited to steroids and immunosuppressants and often ineffective and an ultimately fatal course is common. A lack of translational research is characteristic for the field of DPLD. In part, this is due to the limited availability of well characterized patient cohorts and biomaterials. In this consortium, the nations leading scientists in the field of DPLD have united to:
establish a German DPLD registry and biobank, thus enabling description of the natural course of DPLD, improving the diagnostic standard of specific DPLD and providing most valuable biomaterials for translational research
identify trigger mechanisms, cellular consequences, profibrotic signaling cascades and modifying pathways underlying development of lung fibrosis in some forms of DPLD (focus on sarcoidosis, chronic beryllium disease, Nonspecific Interstitial Pneumonia, pediatric DPLD and lymphangioleiomyomatosis)
- establish novel diagnostic tools and animal models and evaluate new treatment modalities
Our mission statement is clear:
Less dyspnea and better quality of life for patients with DPLD!